Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus XHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus XHANCE.
DECADRON W/ XYLOCAINE vs XHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal.
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Corticosteroid